Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Patient Enrollment on Track in Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV), Topline Results from North ...

Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of H…

Company Hosting Virtual KOL Panel Event Thursday, November 13th at 10:00 AM ETBOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Atea ...